Literature DB >> 1835412

Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice.

S Kamel-Reid1, M Letarte, M Doedens, A Greaves, B Murdoch, T Grunberger, T Lapidot, P Thorner, M H Freedman, R A Phillips.   

Abstract

Bone marrow samples from patients with pre-B acute lymphoblastic leukemia (pre-B ALL), either at diagnosis or at relapse, were transplanted into scid mice to determine whether these freshly obtained leukemic cells could proliferate in vivo and whether there were any differences in their in vivo growth characteristics. Cells from three patients who relapsed within 13 months of diagnosis proliferated rapidly in the murine bone marrow, spleen, and thymus, invaded peripheral organs, and resulted in morbidity and mortality of the animals within 4 to 16 weeks. Cells from two patients who relapsed 3.5 years after diagnosis grew much slower than the early relapse samples, taking up to 30 weeks to infiltrate the bone marrow of recipient mice. In contrast, leukemic cells were absent or were detected at low numbers in scid mice transplanted with cells obtained at diagnosis from three patients who have not yet relapsed. These results show an increased ability of leukemic cells from patients with aggressive lymphoblastic leukemia of poor prognosis to proliferate in scid mice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1835412

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  SCID mice in the study of human autoimmune diseases.

Authors:  M A Duchosal
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.

Authors:  M Hsiao; J Low; E Dorn; D Ku; P Pattengale; J Yeargin; M Haas
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

3.  In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.

Authors:  Christoph le Viseur; Marc Hotfilder; Simon Bomken; Kerrie Wilson; Silja Röttgers; André Schrauder; Annegret Rosemann; Julie Irving; Ronald W Stam; Leonard D Shultz; Jochen Harbott; Heribert Jürgens; Martin Schrappe; Rob Pieters; Josef Vormoor
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

4.  Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB.

Authors:  M Zahidunnabi Dewan; Kazuo Terashima; Midori Taruishi; Hideki Hasegawa; Mamoru Ito; Yuetsu Tanaka; Naoki Mori; Tetsutaro Sata; Yoshio Koyanagi; Michiyuki Maeda; Yoko Kubuki; Akihiko Okayama; Masahiro Fujii; Naoki Yamamoto
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Potential role of natural killer cells in controlling tumorigenesis by human T-cell leukemia viruses.

Authors:  G Feuer; S A Stewart; S M Baird; F Lee; R Feuer; I S Chen
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

6.  Comparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomes.

Authors:  T M Anderson; S D Hess; N K Egilmez; C E Nwogu; J M Lenox; R B Bankert
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-16       Impact factor: 4.553

7.  Immunotoxin studies in a model of human T-cell acute lymphoblastic leukemia developed in severe combined immune-deficient mice.

Authors:  B J Morland; D Boehm; S U Flavell; J A Kohler; D J Flavell
Journal:  Cell Biophys       Date:  1994

8.  High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias.

Authors:  S Morisot; A S Wayne; O Bohana-Kashtan; I M Kaplan; C D Gocke; R Hildreth; M Stetler-Stevenson; R L Walker; S Davis; P S Meltzer; S J Wheelan; P Brown; R J Jones; L D Shultz; C I Civin
Journal:  Leukemia       Date:  2010-08-26       Impact factor: 11.528

9.  Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.

Authors:  D J Flavell; S L Warnes; A L Noss; S U Flavell
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

10.  Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.

Authors:  B J Morland; J Barley; D Boehm; S U Flavell; N Ghaleb; J A Kohler; K Okayama; B Wilkins; D J Flavell
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.